Generation Bio Acquired by XOMA Royalty — Healthcare M&A

XOMA Royalty has completed the acquisition of Generation Bio, a healthcare services other business in California, for $50 million. XOMA Royalty acquires Generation Bio to expand its biotechnology royalty aggregator model, supporting human health programs through structured royalty interests. Generation Bio is a biotech company whose shareholders received $4.2913 per share in cash plus a non-tradeable contingent value right as part of the tender offer process in CA. XOMA Royalty acquisitions were executed as a strategic acquisition and merger acquisition, with about 70% of shares tendered before the February 6, 2026 expiration and the deal closing on February 9, 2026.